Form 4: Recursion Pharmaceuticals CEO Christopher Gibson Reports Stock Transactions

Christopher Gibson, CEO of Recursion Pharmaceuticals, reports multiple transactions involving Class A and Class B Common Stock, including acquisitions, disposals, and conversions, as part of a pre-arranged trading plan.

Summary

• On March 6, 2024, Christopher Gibson, the CEO of Recursion Pharmaceuticals, engaged in several transactions involving the company's Class A and Class B Common Stock.
• These transactions included the conversion of Class B Common Stock to Class A Common Stock, the exercise of stock options, and the sale of Class A Common Stock.
• The sales were executed at weighted average prices ranging from $11.22 to $12.11 per share.
• Gibson also reported transactions involving shares held indirectly through LAHWRAN-3 LLC, LAHWRAN-4 LLC, and the Gibson Family Trust.
• Following these transactions, Gibson directly owns 1,108,524 shares of Class A Common Stock and indirectly controls additional shares through the aforementioned entities.
• The reported transactions were made pursuant to a Rule 10b5-1 trading plan adopted on December 22, 2022.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are part of a pre-planned trading strategy, so they don't necessarily indicate a change in the CEO's confidence in the company. However, sales by insiders can sometimes be perceived negatively.

Positives

• The transactions are part of a pre-arranged Rule 10b5-1 trading plan, suggesting they were planned well in advance and not based on recent insider information.

Negatives

• The sales of Class A Common Stock by the CEO could be interpreted negatively by some investors, although they are part of a pre-arranged plan.

Risks

• While the transactions are part of a pre-arranged plan, significant sales by a CEO could create short-term price volatility.

Future Outlook

The reported transactions are part of an existing trading plan, suggesting continued, pre-determined buying and selling activity.

Industry Context

Insider transactions are common and closely monitored in the pharmaceutical industry. Form 4 filings provide transparency into these transactions, allowing investors to track insider sentiment and potential changes in ownership.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting insider transactions across all publicly traded companies, including pharmaceutical firms like Recursion Pharmaceuticals.
• Companies like Amgen, Pfizer, and Johnson & Johnson also have frequent Form 4 filings reflecting stock transactions by their executives and directors.
• The level of detail provided in this Form 4 is consistent with regulatory requirements and industry norms.

Stakeholder Impact

• The transactions could have a minor impact on shareholders due to the potential for short-term price fluctuations.
• The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates